An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

Phase 1

Completed

• Conditions: Neurofibromatosis 2

• Registration Number: NCT00030043
• Lead Sponsor: FDA Office of Orphan Products Development

Brief Summary

This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Detailed Description

Neurofibromatosis Type 2 (NF2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. Surgical resection of these tumors generally results in the transection of the VIIIth nerve, destruction of the cochlea and auditory nerve, and total hearing loss. Due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. The Auditory Brainstem Implant (ABI) provides the only available intervention to restore some auditory sensation to these patients. An ABI is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus.

The PABI may be placed surgically during tumor resection. Efficacy will be assessed using psychophysical and standard speech reception measures.

Study Timeline

• Study Start: 2001-09
• Status Verified: 2002-01
• Study First Submitted: 2002-01-30
• Study First Submitted QC: 2002-01-30
• Study First Posted: 2002-01-31
• Study Completion: 2003-08
• Last Update Submitted: 2015-03-24
• Last Update Posted: 2015-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

Cochlear Corporation; 🇺🇸 Englewood, Colorado, United States

House Ear Institute; 🇺🇸 Los Angeles, California, United States

Huntington Medical Research Institutes; 🇺🇸 Pasadena, California, United States